donor/recipient (D/R) were: CMV D(À) R(+); EBV D(À) R(À).
There was no history of myeloma in the donor and electrophoresis of serum proteins was normal. The induction was made based on the thymoglobulin for 5 days associated with triple therapy made of cyclosporine, mycophenolate mofetil and prednisolone. The posttransplant period was marked by the immediate resumption of diuresis and renal function. At discharge serum creatinine was 1 mg/dl (63 ml/min/1.73 m 2 according to MDRD Modification of Diet in Renal Disease). While the 1st to 19th month post-transplant period, no major complications was noted; patient was admitted at 20th month for vomiting, diarrhea without fever and hydrops state made of generalized edema, ascites and pleural effusion. Endoscopy and colonoscopy were normal as well as stool examination and stool culture. For the exploration of the state of hydrops, proteinuria was 1 g/24 h with hypoprotidemia to 53 g/l, hypoalbuminemia to 33 g/l, significant hypogammaglobulinemia to 3.1 g/ l and worse of graft function with 2.2 mg/dl of serum creatinine. The urine was sterile without hematuria or pyuria. At Doppler ultrasound, the graft was of normal size, echogenic cortex with resistance index 0.7. A graft biopsy had found allograft glomerulopathy type of acute tubular necrosis and chronic tubulointerstitial lesions without minor or moderate capillaritis peritubular vascular lesions with chronic rejection signs for the classification of Banff: i1 v0 t0 g0 cpt0 ci1 ct1 CG0 CV0 ah0 mm3. The BK virus and CMV PCR were negative. Liver function tests had found a cytolytic cholestasis syndrome with gammaGT to 5 times normal, transaminase (SGOT and SPOT) to 2.5 times normal. There was no liver failure, serology hepatitis B and C were negative. Abdominal ultrasonography was found hepatosplenomegaly ascites with an average of abundance, a trunk door permeable and no bile duct dilatation. On hematological, it was noted a normocytic normochromic anemia than 8 g/dl and ferritin to 2557 ng/ml, a liver biopsy performed showed mixed hepatosiderosis with no lesions of fibrosis or cirrhosis. Echocardiography was unremarkable; T thyroid exploration was normal. A few days later, his general status declined by a high fever (39 8C), worsening of graft function with 4.76 mg/dl of serum creatinine (10 ml/min/1.73 m 2 (MDRD)), and a bicytopenia made of a normochromic normocytic anemia at 6.2 g/dl and agranulocytosis. A bone marrow aspiration and a bone marrow biopsy were made and objectified marrow plasma cell infiltration moderate estimated 20% of monotypic kappa pace. The immunoelectrophoresis and immunofixation plasma proteins showed hypogammaglobulinemia, excessive levels of free kappa light chains to 3100 mg/l with a normal rate of lambda chains. The Bence-Jones proteinuria was positive with excretion of kappa light chains. A replay of biopsy slides of renal graft and liver performed by the team of Poitier University Hospital in France had found Randall deposit type of kappa light chains in the kidney and liver making a finding of renal and liver Randall's disease. The radiography of the skeleton had helped to objectify osteolytic lesions of the skull. Multiple myeloma diagnosed with kidney and liver damage type Randall was then retained. The therapeutic management had been to stop immunosuppressive therapy with hemodialysis back and put under chemotherapy with cyclophosphamide, thalidomide and dexamethasone. After the first treatment, determination of free kappa light chains showed an improvement from 3100 to 1819 mg/l. While the patient was waiting for the second cure, she presented septic shock which led to her death.
Discussion
Randall's disease is a rare disease in the general population. Indeed the description of the first case by Randall et al. in 1976, it took 17 years (1993) to see the publication of two other cases. And on 7241 series of renal biopsy, only 34 cases of Randall disease have been reported, or a prevalence of 0.47%. 3, 14, 15 In renal transplant population, Randall's disease is much rarer. Randall recurrence of post-kidney transplant disease is much more described unlike that which occurs de novo. And only 11 cases of de novo post-renal transplantation Randall disease have been reported in the literature. [9] [10] [11] [12] [13] Although de novo nature is always difficult to say because the kidney biopsies, bone marrow and bone marrow aspiration are not routinely performed in the absence of signs suggestive, we based our case on the negativity of evocative clinical and biological signs in the pre-transplant period as well as for the donor and for the recipient. It may also sometimes be a latent form that the post-transplant immunosuppression revealed as is the case reported by Balamuthusamy et al. 12 Speaking of risk factors for the de novo Randall disease post-transplant, they are not clearly understood. However, they seem to be similar to those at the origin of post-transplant lymphoproliferative syndromes such as: primary EBV infection or reactivation of co-infection with CMV or Hepatitis C virus 16, 17 ; immunosuppression induction with antilymphocyte serum and use long-term anti-calcineurins 16, 18, 19 ;
HLA incompatibility especially HLA-B. [20] [21] [22] In our case, the patient has been induced at the base thymoglobulin and received the anticalcineurin in its maintenance therapy. Unlike other cases of de novo Randall's disease post-renal transplant previously reported, the case of our patient particularized by the existence of an associated liver injury. Although extra renal damage had already described in Randall disease, they were inconsistently reported in the de novo post-transplant cases. 13 Therapeutically, like other reported cases, we encountered difficulties in the management. In fact there is no clearly defined strategy for the management of cases of de novo Randall disease post-transplant. In the cases where the Randall disease is associated with a myeloma, treatment includes chemotherapy of myeloma with the reduction of immunosuppression. Knowing that the diminish of immunosuppression leads to a greater risk of graft dysfunction and chemotherapy present a significant risk of infection. Sometimes in case of dysfunction of the graft at the time of diagnosis of the disease, immunosuppression is defatted with quickly return to dialysis. Other treatment such as plasma exchange, immunotherapy are being tested. 10, 23, 24 In our case where a myeloma is associated with graft dysfunction, immunosuppression has been rapid diminish with the back on dialysis and administration of the first course of chemotherapy. Our patient died of septic shock after the first course of chemotherapy as is also the case for the patient reported by Savenkoff et al. who died in an array of septic shock after chemotherapy. 25 
Conclusion
A de novo Randall disease post-transplant is a very rarely. No formal etiology has been identified. Also no therapeutic strategy has been clearly defined it also poses a problem of therapeutic engaged. In cases where it is associated with a myeloma, treatment usually involves chemotherapy and decreased immunosuppression. That was the case for our patient. However this strategy has serious consequences including graft loss related to lower risk of immunosuppression and increased risk of infection. Besides our patient as others died from septic shock after the first course of chemotherapy. It is important to set up a group of multidisciplinary study including in particular the nephrologists and hematologists to develop a strategy for the management of post-kidney transplant Randall disease to minimize the risks.
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The consent of the patient was obtained for publication of his case.
